Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 11(1): 23462, 2021 12 06.
Artigo em Inglês | MEDLINE | ID: mdl-34873203

RESUMO

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. The search included studies through 11-May-2020. Selection criteria included studies evaluating efficacy and safety outcomes of medical cannabinoids (tetrahydrocannabinol, cannabidiol and other cannabis derivatives) versus control in children, independently assessed by two reviewers. Eight studies were included, all of which are randomized controlled trials. Cannabidiol is associated with 50% reduction in seizures rate (Relative Risk (RR) = 1.69, 95% CI [1.20-2.36]) and caregiver global impression of change (Median Estimated difference = (- 1), 95%CI [- 1.39-(- 0.60)]) in Dravet syndrome, compared to placebo. While cannabidiol was associated with a reduction in reported seizure events (RR = 0.59, 95% CI [0.36-0.97]), no association was found in products contained also tetrahydrocannabinol (RR = 1.35, 95% CI [0.46-4.03]). Higher dose of cannabidiol was associated with decreased appetite (RR = 2.40, 95% CI [1.39-4.15]). A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. However, cannabidiol is also associated with decreased appetite. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.


Assuntos
Canabinoides/efeitos adversos , Canabinoides/uso terapêutico , Maconha Medicinal/efeitos adversos , Maconha Medicinal/uso terapêutico , Animais , Criança , Epilepsias Mioclônicas/tratamento farmacológico , Humanos
2.
Nucleic Acids Res ; 39(13): 5704-14, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21450806

RESUMO

Human nuclear RNase P is required for transcription and processing of tRNA. This catalytic RNP has an H1 RNA moiety associated with ten distinct protein subunits. Five (Rpp20, Rpp21, Rpp25, Rpp29 and Pop5) out of eight of these protein subunits, prepared in refolded recombinant forms, bind to H1 RNA in vitro. Rpp20 and Rpp25 bind jointly to H1 RNA, even though each protein can interact independently with this transcript. Nuclease footprinting analysis reveals that Rpp20 and Rpp25 recognize overlapping regions in the P2 and P3 domains of H1 RNA. Rpp21 and Rpp29, which are sufficient for reconstitution of the endonucleolytic activity, bind to separate regions in the catalytic domain of H1 RNA. Common themes and discrepancies in the RNA-protein interactions between human nuclear RNase P and its related yeast and archaeal counterparts provide a rationale for the assembly of the fully active form of this enzyme.


Assuntos
Subunidades Proteicas/metabolismo , RNA/metabolismo , Ribonuclease P/metabolismo , Autoantígenos/genética , Autoantígenos/metabolismo , Sequência de Bases , Sítios de Ligação , Humanos , Magnésio/farmacologia , Dados de Sequência Molecular , Dobramento de Proteína , Subunidades Proteicas/química , Subunidades Proteicas/genética , RNA/química , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Ribonuclease P/química , Ribonuclease P/genética , Ribonucleases/genética , Ribonucleases/metabolismo , Ribonucleoproteínas/genética , Ribonucleoproteínas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...